A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Trial Profile

A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Cediranib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Platinum complexes
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ICON6
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 24 Mar 2017 Results of Quality of Life (QOL) sub-study published in the Cancer
    • 21 Sep 2016 According to an AstraZeneca media release, the company has decided to withdraw the Marketing Authorisation Application (MAA) submitted to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for cediranib. The decision to withdraw the MAA was based on outstanding health authority questions that remain at this late stage of the review process.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top